T80.311S ABO incompatibility with delayed hemolytic transfusion reaction, sequela

Name of the Condition

• ABO incompatibility with delayed hemolytic transfusion reaction, sequela.

Summary

This condition represents the residual or chronic effects following a delayed hemolytic transfusion reaction due to ABO incompatibility. It reflects ongoing or late manifestations of the immune-mediated destruction of red blood cells, which may persist after the acute phase of the reaction. Sequelae can include persistent hemolysis, organ dysfunction, or other long-term complications resulting from the initial transfusion event.

Causes

The sequela arises from a prior delayed hemolytic transfusion reaction caused by ABO incompatibility. This occurs when blood or blood products with incompatible ABO antigens were transfused, triggering an immune response that destroyed donor red blood cells. The residual effects stem from the body's continued response to the initial antigen-antibody interaction or damage from the acute phase.

Risk Factors

• Prior transfusion with ABO-incompatible blood products
• Undetected ABO mismatches during initial transfusion
• Inadequate crossmatching or blood typing before transfusion
• Use of pooled plasma or platelet products with mixed ABO types
• Delayed recognition of the initial reaction, allowing progression to sequelae

Symptoms

• Persistent fatigue or weakness
• Jaundice or elevated bilirubin levels
• Recurrent hemoglobinuria (dark urine)
• Chronic kidney impairment or dysfunction
• Unexplained anemia or hemolysis markers
• Organ-specific complications (e.g., hepatic or renal)

Diagnosis

Diagnosis involves reviewing the patient's transfusion history and confirming a prior delayed hemolytic transfusion reaction due to ABO incompatibility. Laboratory tests may show ongoing hemolysis (e.g., elevated LDH, low haptoglobin) or organ damage. Imaging or functional assessments may be used to evaluate sequelae like renal or hepatic impairment. The timeline of symptoms relative to the transfusion event is critical for correlation.

Treatment Options

Management focuses on addressing the residual effects and preventing further complications. This may include monitoring for ongoing hemolysis, supporting organ function (e.g., renal protection), and treating anemia. In some cases, additional interventions for organ damage or immune modulation may be necessary. Transfusion practices are reviewed to prevent recurrence.

Prognosis and Follow-Up

Prognosis depends on the severity of the initial reaction and the extent of organ damage. Most patients recover with appropriate management, but some may experience chronic effects. Follow-up includes regular monitoring of hemolysis markers, organ function, and blood counts. Long-term care may be required for persistent complications like renal impairment.

Complications

• Chronic kidney disease or failure
• Persistent hemolytic anemia
• Hepatic dysfunction or damage
• Increased risk of future transfusion reactions
• Systemic inflammatory response sequelae

Lifestyle & Prevention

• Ensure accurate blood typing and crossmatching before transfusions
• Use leukoreduced or washed blood products when appropriate
• Maintain clear documentation of transfusion events
• Educate patients on reporting new symptoms post-transfusion
• Follow institutional protocols for transfusion safety

When to Seek Professional Help

Seek immediate medical attention for symptoms like severe fatigue, jaundice, dark urine, or signs of organ dysfunction (e.g., reduced urine output, confusion). These may indicate worsening sequelae or new complications requiring urgent evaluation.

Tips for Medical Coders

Code T80.311S is used for ABO incompatibility with delayed hemolytic transfusion reaction, sequela. Document the prior transfusion event, confirmation of ABO incompatibility, and evidence of residual effects (e.g., lab results, clinical findings) to support the sequela diagnosis. Ensure the sequence aligns with the timing of the initial reaction and the persistence of symptoms or complications.